The latest biotech news

News and Trends 11 May 2017

HIV Treatment Development Extends Life Expectancy by 10 Years

According to a new study, the life expectancy of 20-year-olds starting HIV treatment has increased by a decade in the EU and North America. A massive new study from the UK was published today in The Lancet HIV. The study tracked how many HIV patients died during the first three years of HIV treatment, their cause […]

May 11, 2017 - 3 minutesmins - By Melanie De Almeida

News and Trends 10 May 2017

Oxford Synbio Startup with Eyes on Therapeutics gets hold of CRISPR

Synbio startup Oxford Genetics has licensed CRISPR from Emmanuelle Charpentier’s company, ERS Genomics, to boost its platform. Synthetic biology has so far remained on the fringe of biotech, but one company, Oxford Genetics, is demonstrating its use in therapeutics. To bolster its efforts, the startup has secured a nonexclusive license from ERS Genomics, which represents […]

May 10, 2017 - 2 minutesmins - By Evelyn Warner

News and Trends 10 May 2017

Roche’s Checkpoint Inhibitor Misfires in Late-Stage Trials

Roche’s drug tecentriq just failed a late-stage Phase III study in bladder cancer, raising questions about its future as an anticipated blockbuster. Roche and Genentech have been pushing their checkpoint inhibitor tecentriq onto the market last year, going for a number of different indications including bladder cancer and non-small cell lung cancer (NSCLC). After the FDA handed out accelerated approval in May 2016, […]

May 10, 2017 - 3 minutesmins - By Melanie De Almeida

News and Trends 10 May 2017

Experts say the Microbiome could overtake Genetics as the Next Big Thing

Yesterday, a panel of experts at BioTrinity discussed the huge possibilities offered by the young microbiome field, which could soon overtake genetics. Scientists and investors worldwide are starting to turn to the microbiome, which many believe hold the key to human health. The microorganisms that live in us and on us have shown to play […]

May 10, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 9 May 2017

AI-Based Drug Discovery Biotech is Recruited by Sanofi in €250M Deal

As part of the deal with Sanofi, Exscientia will tackle the discovery and design of new bispecific drugs using artificial intelligence algorithms. Exscientia, based in Scotland, is a company that uses artificial intelligence (AI) to develop new drugs faster. Its edge-cutting technology has caught the attention of Sanofi, which is offering Exscientia research funding and […]

May 9, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

hypermutation biofuels antimicrobial resistance cancer

News and Trends 9 May 2017

Hypermutation could be the Key to Biofuels – and Antibiotic Resistance

Instead of taking a spa vacation, stressed out bacteria start mutating their DNA fast. This nearly suicidal behavior can yield a lucky survivor in nature. For us, it could mean new strategies for biofuel production and fighting antibiotic resistance, researchers say. Researchers from the Centre of Microbial and Plant Genetics at KU Leuven, in Belgium, are shining […]

May 9, 2017 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 8 May 2017

The EU Approves New Treatment for a Rare Pediatric Cancer

Update (08/05/2017): The European Commission has granted marketing authorization to Apeiron Biologic’s APN311 in the rare pediatric cancer neuroblastoma. Originally published on 27/03/2017 Apeiron Biologics has announced that the EMA’s CHMP has recommended the approval of APN311 for immunotherapy of high-risk neuroblastoma. Apeiron Biologics is a Vienna-based biotech company developing immunological approaches to treat cancer. […]

May 8, 2017 - 3 minutesmins - By Melanie De Almeida

News and Trends 8 May 2017

Swedish Biotech Faces Another Phase III Flop in Multiple Sclerosis

Teva and Active Biotech have failed Phase III with their Multiple Sclerosis drug laquinimod to treat the relapsing-remitting form of the disease. Teva and Active Biotech have faced another setback with their long-expected successor to Teva’s Copaxone, laquinimod, for the treatment of Multiple Sclerosis (MS). The drug failed to meet the primary endpoint, trying to improve the […]

May 8, 2017 - 2 minutesmins - By Melanie De Almeida

News and Trends 8 May 2017

French Researchers Discover a Target to Prevent Zika Birth Defects

Researchers from the Institut Pasteur and the Inserm have identified a protein target that, when overexpressed, can block Zika infections. The recent Zika epidemics in the Pacific and South America has led the World Health Organization (WHO) to declare a state of global emergency. One of the biggest concerns at the moment is that the […]

May 8, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Immunocore GSK Immuno oncology collaboration

News and Trends 8 May 2017

Immunocore Boosts its Collaboration with GSK with new Lead Compound

Immunocore has singled out a new lead candidate in its immuno-oncology discovery program with GSK, triggering an undisclosed milestone payment to Immunocore. Based in Oxford, Immunocore is one of the hottest biotechs in the immuno-oncology space, which was able to raise one of the largest European private funding rounds ever (€300M) and is backed by […]

May 8, 2017 - 2 minutesmins - By Melanie De Almeida

Seuss Consulting CRO Sponsor partnerhsip

News and Trends 8 May 2017

Top 5 Mistakes that Will Doom a CRO-Supplier Partnership Before it Starts

A healthy relationship between a trial sponsor and the CRO or supplier can be the key to success – here is a list of how to address the biggest challenges. By 2020, 72% of clinical trials are projected to be outsourced to contract research organizations (CROs), compared to just 23% in 2012. The main reason […]

May 8, 2017 - 7 minutesmins - By External Contributor

News and Trends 5 May 2017

Forget Chemical Synthesis, Yeast can Now Synthesize Complex Antibiotics

A new study presents a novel synthetic biology approach for antibiotic synthesis in yeast that could tackle the huge challenge of antibiotic resistance. Scientists at Imperial College London have hacked their way into introducing complex biosynthesis pathways in the baker’s yeast Saccharomyces cerevisiae. In particular, they focused on the production of non-ribosomal peptides (Nrp), a group of […]

May 5, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

HIV Treatment Development Extends Life Expectancy by 10 Years

Oxford Synbio Startup with Eyes on Therapeutics gets hold of CRISPR

Roche’s Checkpoint Inhibitor Misfires in Late-Stage Trials

Experts say the Microbiome could overtake Genetics as the Next Big Thing

AI-Based Drug Discovery Biotech is Recruited by Sanofi in €250M Deal

Hypermutation could be the Key to Biofuels – and Antibiotic Resistance

The EU Approves New Treatment for a Rare Pediatric Cancer

Swedish Biotech Faces Another Phase III Flop in Multiple Sclerosis

French Researchers Discover a Target to Prevent Zika Birth Defects

Immunocore Boosts its Collaboration with GSK with new Lead Compound

Top 5 Mistakes that Will Doom a CRO-Supplier Partnership Before it Starts

Forget Chemical Synthesis, Yeast can Now Synthesize Complex Antibiotics

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!